What sets probiotic-induced cancer-reactive T-cells apart?

This project builds on striking clinical observations showing that a low-cost probiotic can dramatically improve long-term survival in patients with lung and other cancers when given alongside standard treatments. Understanding how such a simple intervention can produce profound benefits could transform cancer care, particularly in resource-limited settings.

Researchers in Cardiff have discovered that this probiotic activates a rare population of immune cells, Vγ9Vδ2 T-cells, which can directly kill a wide range of cancer cells. Crucially, only a small subset of these cells—uniquely induced by the probiotic—have this anticancer activity. This project will determine what makes these cells special and why they outperform similar immune cells activated by conventional drugs.

By uncovering how the gut microbiota can stimulate potent anticancer immunity, this work could lead to new, affordable therapies that enhance existing cancer treatments. Such approaches have strong potential to benefit patients in Wales quickly, as the probiotic can be tagged onto standard treatments the hundreds of cancer patients in Wales undergo routinely each day. This will ultimately reduce costs while improving outcomes across multiple cancer types.